GlassScriptPhysician profile
Pankaj V Patel
NPI 1952314775
$6,755.46
in general payments reported to CMS, 2019-2025
31 companies · $1,556 in 2025
The $1,556 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,723 · 2020: $356 · 2021: $495 · 2022: $791 · 2023: $558 · 2024: $1,276 · 2025: $1,556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,749 · Travel and Lodging: $642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,748.93 |
| Travel and Lodging | $641.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $1,292.29 | 2019 | |
| Cvrx, INC. | $783.57 | 2025 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $662.61 | 2019-2025 | Farxiga, Lokelma |
| Merck Sharp & Dohme LLC | $496.08 | 2021-2025 | Verquvo |
| Pfizer INC. | $496.04 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $438.84 | 2019-2025 | Jardiance |
| Boston Scientific Corporation | $363.15 | 2020-2023 | Wolverine Coronary Cutting Balloon |
| Abiomed | $353.56 | 2022-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $292.98 | 2019-2025 | |
| Amgen INC. | $281.73 | 2023-2025 | Repatha, Repatha |
| Medtronic, INC. | $191.41 | 2021-2025 | Abre, Everflex Protege Everflex |
| Edwards Lifesciences Corporation | $148.27 | 2024 | Sapien 3 Ultra Resilia |
| Janssen Pharmaceuticals, INC | $144.64 | 2020-2024 | Xarelto |
| Innovation Technologies INC | $123.29 | 2022 | |
| Amarin Pharma, INC. | $96.57 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $60.41 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $59.52 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $55.86 | 2024 | |
| Tactile Systems Technology INC | $55.15 | 2019 | |
| Esperion Therapeutics, INC. | $54.63 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $52.63 | 2024 | Onpattro |
| Kowa Pharmaceuticals America, INC. | $46.14 | 2020-2021 | |
| Kiniksa Pharmaceuticals, LTD. | $40.51 | 2023 | Arcalyst |
| Abbott Laboratories | $29.75 | 2021-2023 | Cardiomems |
| Actelion Pharmaceuticals US, INC. | $29.52 | 2024 | Opsumit |
| Cordis US Corp. | $24.30 | 2023 | Zephyr |
| Daiichi Sankyo INC. | $22.85 | 2025 | Injectafer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.30 | 2022 | |
| Inogen, INC. | $14.33 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $13.69 | 2021 | |
| Vivaquant INC, Dba Rhythm Express | $8.84 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pankaj Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.